The current standards of care involve using anti-VEGF agents, which selectively target extracellular VEGF. We've been doing this for years and those drugs do a good job, but there are limitations ...
STOCKHOLM -- Two VEGF-targeting gene therapies for neovascular age-related macular degeneration (nAMD) substantially reduced treatment burden while preserving visual acuity, according to results ...
NORTHBROOK, Ill., March 26, 2024 /PRNewswire/ -- Iveric Bio, An Astellas Company (TSE: 4503, President and CEO: Naoki Okamura, "Astellas"), today announced the U.S. Centers for Medicare and Medicaid ...
Please provide your email address to receive an email when new articles are posted on . SEATTLE — A laboratory study showed significant variation in accuracy and residual volume among syringes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback